What does the Copaxone deal have to do with any of this? Copaxone is sui generis.
I don't think there is anyone on this board who predicted a substantially lower 'royalty' rate (whatever you want to call the % of $ flowing from sale of mBio) than for Copaxone even after they are doing all the early work on their nickle. I'd bet if I surf around I can find implicit assumption from many that there would be a higher GM than these terms imply.
Market Data 
Markets 
AI
